AlzeCure Pharma (ALZCUR) - Total Assets
Based on the latest financial reports, AlzeCure Pharma (ALZCUR) holds total assets worth Skr66.59 Million SEK (≈ $7.17 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore ALZCUR cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
AlzeCure Pharma - Total Assets Trend (2017–2024)
This chart illustrates how AlzeCure Pharma's total assets have evolved over time, based on quarterly financial data. See ALZCUR net asset value for net asset value and shareholders' equity analysis.
AlzeCure Pharma - Asset Composition Analysis
Current Asset Composition (December 2024)
AlzeCure Pharma's total assets of Skr66.59 Million consist of 99.4% current assets and 0.7% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 91.5% |
| Accounts Receivable | Skr2.71 Million | 7.9% |
| Inventory | Skr0.00 | 0.0% |
| Property, Plant & Equipment | Skr207.00K | 0.6% |
| Intangible Assets | Skr17.00K | 0.1% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how AlzeCure Pharma's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see ALZCUR market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: AlzeCure Pharma's current assets represent 99.4% of total assets in 2024, a decrease from 99.5% in 2017.
- Cash Position: Cash and equivalents constituted 91.5% of total assets in 2024, down from 96.4% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 7.9% of total assets.
AlzeCure Pharma Competitors by Total Assets
Key competitors of AlzeCure Pharma based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Syndax Pharmaceuticals Inc
NASDAQ:SNDX
|
USA | $472.67 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $506.75 Million |
|
Chengdu Kanghua Biological Products
SHE:300841
|
China | CN¥3.94 Billion |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488
|
China | CN¥1.84 Billion |
AlzeCure Pharma - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.75 | 6.02 | 16.38 |
| Quick Ratio | 4.75 | 6.02 | 16.38 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Skr49.12 Million | Skr35.36 Million | Skr108.79 Million |
AlzeCure Pharma - Advanced Valuation Insights
This section examines the relationship between AlzeCure Pharma's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.30 |
| Latest Market Cap to Assets Ratio | 2.22 |
| Asset Growth Rate (YoY) | 7.6% |
| Total Assets | Skr34.44 Million |
| Market Capitalization | $76.43 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values AlzeCure Pharma's assets at a significant premium (2.22x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: AlzeCure Pharma's assets grew by 7.6% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for AlzeCure Pharma (2017–2024)
The table below shows the annual total assets of AlzeCure Pharma from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | Skr34.44 Million ≈ $3.71 Million |
+7.61% |
| 2023-12-31 | Skr32.00 Million ≈ $3.44 Million |
-54.82% |
| 2022-12-31 | Skr70.84 Million ≈ $7.62 Million |
+55.18% |
| 2021-12-31 | Skr45.65 Million ≈ $4.91 Million |
-61.26% |
| 2020-12-31 | Skr117.83 Million ≈ $12.68 Million |
-36.91% |
| 2019-12-31 | Skr186.75 Million ≈ $20.10 Million |
-21.46% |
| 2018-12-31 | Skr237.78 Million ≈ $25.59 Million |
+324.83% |
| 2017-12-31 | Skr55.97 Million ≈ $6.02 Million |
-- |
About AlzeCure Pharma
AlzeCure Pharma AB (publ) operates as a pharmaceutical company that develops drug therapies for the treatment of severe diseases and conditions that affect the central nervous system. The company is involved in the development of drug candidates based on the NeuroRestore, Alzstatin, and Painless research platforms. Its products pipeline includes ACD856 for the treatment of Alzheimer's disease, sl… Read more